In addition, targeting the FTO and PDK1/AKT signaling axes with FB23 and BX-912 suppresses breast carcinoma progression, augments cytotoxic T-lymphocyte functionality, and synergistically enhances the therapeutic efficacy of the anti-PD-1/PD-L1 immunotherapy atezolizumab in preclinical models [283]. This evidence concerns the gene CD274 and breast carcinoma.